menu
    • menu
    [{"orgOrder":0,"company":"Attovia Therapeutics","sponsor":"Goldman Sachs Alternatives","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Series B Financing","leadProduct":"ATTO-1310","moa":"Undisclosed","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Attovia Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Attovia Therapeutics \/ Goldman Sachs Alternatives","highestDevelopmentStatusID":"5","companyTruncated":"Attovia Therapeutics \/ Goldman Sachs Alternatives"},{"orgOrder":0,"company":"Attovia Therapeutics","sponsor":"Frazier Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Attovia Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Attovia Therapeutics \/ Frazier Life Sciences","highestDevelopmentStatusID":"3","companyTruncated":"Attovia Therapeutics \/ Frazier Life Sciences"}]

    Find Clinical Drug Pipeline Developments & Deals by Attovia Therapeutics

    Menu

    Attovia Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Attovia Therapeutics

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Attovia Therapeutics

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ATTO-1310

                            Therapeutic Area : Dermatology

                            Study Phase : IND Enabling

                            Sponsor : Goldman Sachs Alternatives

                            Deal Size : $105.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Attovia Raises $105 Million in Oversubscribed Series B Financing

                            Details : The net proceeds will advance ATTO-1310 and ATTO-002 through initial clinical data readouts, expand the immunology/inflammation pipeline, and further develop the ATTOBODY™ platform.

                            Product Name : ATTO-1310

                            Product Type : Other Large Molecule

                            Upfront Cash : Undisclosed

                            September 05, 2024

                            Lead Product(s) : ATTO-1310

                            Therapeutic Area : Dermatology

                            Highest Development Status : IND Enabling

                            Sponsor : Goldman Sachs Alternatives

                            Deal Size : $105.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Attovia Therapeutics

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Attovia Therapeutics

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Study Phase : Discovery Platform

                            Sponsor : Frazier Life Sciences

                            Deal Size : $60.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Attovia Therapeutics Launches with $60 Million Series A Financing to Unlock Potential of Novel Biparatopic Nan...

                            Details : The proceeds will be used to achieve clinical proof-of-concept on its lead program in immune-mediated disease, nominate additional candidates across the its core areas of focus in immunology and oncology, as well as continue to advance the core Attobody ...

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            June 20, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Highest Development Status : Discovery Platform

                            Sponsor : Frazier Life Sciences

                            Deal Size : $60.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth